Press Releases AstraZeneca PLC Nasdaq Stockholm

Equities

AZN

GB0009895292

Market Closed - Nasdaq Stockholm Other stock markets 11:29:38 2024-05-31 am EDT			5-day change	1st Jan Change
1,643 ^SEK	+1.08%		-1.76%	+21.39%

02:00pm	Astrazeneca Safety Profile Of Enhertu Was Consistent With Previous Breast Cancer Clinical Trials With No New Safety Concerns Identified	RE
02:00pm	ASTRAZENECA: SAFETY PROFILE OF ENHERTU WAS CONSISTENT WITH PREV…	RE

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Daiichi Sankyo - Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial	May. 28	AQ
Expansion of AstraZeneca's flagship health equity programme Healthy Heart Africa	May. 28	AQ
Expansion of AstraZeneca’s flagship health equity programme Healthy Heart Africa The programme aims to improve health outcomes, with a focus on increasing awareness of the symptoms and risks of hypertension	May. 28	AQ
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial	May. 27	BU
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)	May. 23	BU
AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024	May. 22	BU
Astrazeneca looks to double revenue in 'new era of growth'	May. 22	AQ
INSIDE XP POWER REJECTS BID ...	May. 22	AQ
AstraZeneca : Oncology presentation	May. 21	PU
AstraZeneca : Rare Disease presentation	May. 21	PU
AstraZeneca : BioPharmaceuticals presentation	May. 21	PU
AstraZeneca : Investor Day Agenda	May. 21	PU
AstraZeneca : Investor Day Biographies	May. 21	PU
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030	May. 21	BU
Astrazeneca set to build cancer drug plant in Singapore	May. 21	AQ
AstraZeneca announces $1.5b ADC manufacturing facility	May. 20	AQ
Astrazeneca - New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease	May. 20	AQ
AstraZeneca : plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore - Form 6-K	May. 20	PU
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease	May. 19	BU
AlzeCure Pharma AB - Eli Lilly's and AstraZeneca's former head of research Dr. Jan Lundberg elected as a new board member	May. 16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT